Source: VETSTEM Press Service
VETSTEM LLC is pleased to announce an important milestone in the development of VEZOTIL®: the update of packaging design and the addition of a new production site. These changes reflect our commitment to continuously increasing product volume and expanding the geography of its supply.
New Production Site: Stavropol Biopharma
From May 2026, the production of VEZOTIL® will be carried out additionally at the Stavropol Biopharma Research and Production Facility, one of the largest and most technologically advanced enterprises in the veterinary pharmaceutical industry in Russia.
Advantages of the New Production Site:
International Quality Standards
NPF "Stavropolskaya Biofabrika" is certified according to GMP (Good Manufacturing Practice) standards, which guarantees compliance with the strictest requirements for pharmaceutical production at all stages — from input control of raw materials to release of finished products.
Modern Analytical Equipment
Production is equipped with high-precision control and measuring equipment from the world's leading manufacturers, which provides multi-stage quality control of each series of the drug.
Scaling and Stability of Supplies
The capacities of Stavropol Biopharma allow significant increase in production volumes of VEZOTIL® and guarantee uninterrupted supplies of the drug not only throughout the Russian Federation, but also beyond.
Updated Design and New Bottles
With the addition of another production site, VEZOTIL® has a completely updated appearance:
- Modern packaging design
- New bottles
The new packaging has been designed to meet modern requirements for veterinary products.
Starting from May 2026, there will be two types of VEZOTIL® packaging available for purchase:
- New packaging — produced by NPF Stavropolskaya Biofabrika, with an updated design
- Old packaging — produced by Deco-Pharm LLC, with a classic design
Important: Both versions of the product are completely identical in terms of:
- Composition
- Quality and effectiveness
- Indications for use
- Dosing protocols
- Storage conditions
The only difference is the appearance of the packaging and the indication of the production site. You can use both versions as usual — no changes to work protocols are required.
What Remains Unchanged?
Despite the update of production and design, the main characteristics of VEZOTIL® that make it valuable for specialists remain the same:
- The composition of the drug — the same proven combination of tiletamine and zolazepam
- Effectiveness — reliable anesthesia with predictable effect
- Safety — minimal risks of complications when following the protocols
- Application protocols — all the usual dosage schemes are maintained
- Registration certificate — valid, without changes